JP2024509904A - 新規なＤＡＲＰｉｎに基づく多重特異性Ｔ細胞エンゲージャ - Google Patents

新規なＤＡＲＰｉｎに基づく多重特異性Ｔ細胞エンゲージャ Download PDF

Info

Publication number
JP2024509904A
JP2024509904A JP2023554922A JP2023554922A JP2024509904A JP 2024509904 A JP2024509904 A JP 2024509904A JP 2023554922 A JP2023554922 A JP 2023554922A JP 2023554922 A JP2023554922 A JP 2023554922A JP 2024509904 A JP2024509904 A JP 2024509904A
Authority
JP
Japan
Prior art keywords
protein
darpin
recombinant protein
release
cells
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023554922A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024509904A5 (enExample
Inventor
マッテオ ビアンキ
ニーナ レシュケ
セバスティアン グリム
クリスティアン ライヒェン
ベルント シュレーレス
ヴィクター レヴィツキー
Original Assignee
モレキュラー パートナーズ アクチェンゲゼルシャフト
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by モレキュラー パートナーズ アクチェンゲゼルシャフト filed Critical モレキュラー パートナーズ アクチェンゲゼルシャフト
Publication of JP2024509904A publication Critical patent/JP2024509904A/ja
Publication of JP2024509904A5 publication Critical patent/JP2024509904A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Amplifiers (AREA)
  • Liquid Crystal Substances (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
JP2023554922A 2021-03-09 2022-03-09 新規なＤＡＲＰｉｎに基づく多重特異性Ｔ細胞エンゲージャ Pending JP2024509904A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202163158539P 2021-03-09 2021-03-09
US63/158,539 2021-03-09
US202163172973P 2021-04-09 2021-04-09
US63/172,973 2021-04-09
US202163265184P 2021-12-09 2021-12-09
US63/265,184 2021-12-09
PCT/IB2022/052126 WO2022190016A1 (en) 2021-03-09 2022-03-09 Novel darpin based multi-specific t-cell engagers

Publications (2)

Publication Number Publication Date
JP2024509904A true JP2024509904A (ja) 2024-03-05
JP2024509904A5 JP2024509904A5 (enExample) 2025-03-18

Family

ID=81327872

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023554922A Pending JP2024509904A (ja) 2021-03-09 2022-03-09 新規なＤＡＲＰｉｎに基づく多重特異性Ｔ細胞エンゲージャ

Country Status (11)

Country Link
US (2) US11834504B2 (enExample)
EP (1) EP4304731A1 (enExample)
JP (1) JP2024509904A (enExample)
KR (1) KR20230155464A (enExample)
AU (1) AU2022234894A1 (enExample)
BR (1) BR112023018293A2 (enExample)
CA (1) CA3211381A1 (enExample)
CO (1) CO2023012681A2 (enExample)
IL (1) IL305677A (enExample)
MX (1) MX2023010543A (enExample)
WO (1) WO2022190016A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112023018293A2 (pt) * 2021-03-09 2023-10-31 Molecular Partners Ag Acopladores de célula t multiespecíficos à base de darpin
EP4724486A1 (en) * 2023-06-06 2026-04-15 Molecular Partners AG Recombinant cd2 binding proteins and their use
WO2025163083A1 (en) * 2024-01-31 2025-08-07 Molecular Partners Ag Recobminant dll3 binding proteins and their use
WO2025181039A1 (en) 2024-03-01 2025-09-04 Molecular Partners Ag Therapeutic combinations comprising a multi-specific t cell engager

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014501509A (ja) * 2010-11-26 2014-01-23 モレキュラー・パートナーズ・アーゲー 血清アルブミンに結合する設計リピートタンパク質
JP2018511327A (ja) * 2015-04-02 2018-04-26 モレキュラー パートナーズ アクチェンゲゼルシャフト 血清アルブミンに対する結合特異性を有する設計アンキリンリピートドメイン
JP2019512272A (ja) * 2016-03-21 2019-05-16 エルスター セラピューティクス， インコーポレイテッド 多重特異性および多機能性分子ならびにその使用
WO2019200022A1 (en) * 2018-04-11 2019-10-17 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
WO2020245746A1 (en) * 2019-06-04 2020-12-10 Molecular Partners Ag Multispecific proteins

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1332209B1 (en) 2000-09-08 2009-11-11 Universität Zürich Collections of repeat proteins comprising repeat modules
JP2008519590A (ja) 2004-11-12 2008-06-12 バイエル・シエーリング・ファーマ アクチエンゲゼルシャフト 組換えニューカッスル病ウィルス
BRPI0613593A2 (pt) 2005-07-08 2011-01-18 Univ Zuerich método de teste "phage display" filamentoso, vetor de fago ou de fagomìdeo e biblioteca de vetores de fago ou fagomìdeo
US9365629B2 (en) 2007-09-24 2016-06-14 University Of Zurich Designed armadillo repeat proteins
BRPI0921469B1 (pt) 2008-11-03 2022-01-18 Molecular Partners Ag Proteínas de ligação que inibem a interação com o receptor de vegf-a, composição farmacêutica
AR081361A1 (es) 2010-04-30 2012-08-29 Molecular Partners Ag Proteinas de union modificadas que inhiben la interaccion de receptor del factor de crecimiento endotelial vascular de glicoproteina a vegf-a
EA201391607A1 (ru) 2011-04-29 2014-04-30 Янссен Байотек, Инк. Связывающие il4/il13 белки с повторами и их применение
WO2014001442A1 (en) 2012-06-28 2014-01-03 Molecular Partners Ag Designed ankyrin repeat proteins binding to platelet-derived growth factor
WO2014060365A1 (en) 2012-10-15 2014-04-24 Universität Zürich Prorektorat Mnw Bispecific her2 ligands for cancer therapy
EP2738180A1 (en) 2012-11-30 2014-06-04 Molecular Partners AG Binding proteins comprising at least two binding domains against HER2.
EP2789630A1 (en) 2013-04-09 2014-10-15 EngMab AG Bispecific antibodies against CD3e and ROR1
CN105209483B (zh) 2013-05-31 2021-07-27 分子组合公司 与肝细胞生长因子结合的设计锚蛋白重复蛋白
EP2839842A1 (en) 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
US20180333296A1 (en) * 2015-09-02 2018-11-22 Dose Medical Corporation Drug delivery implants as intraocular drug depots and methods of using same
CN109790206A (zh) 2016-09-22 2019-05-21 分子组合公司 重组结合蛋白及其用途
WO2019195535A1 (en) 2018-04-05 2019-10-10 Novartis Ag Trispecific binding molecules against cancers and uses thereof
WO2020068653A1 (en) * 2018-09-24 2020-04-02 Aerpio Pharmaceuticals, Inc. MULTISPECIFIC ANTIBODIES THAT TARGET HPTP - β (VE-PTP) AND VEGF
JP7611173B2 (ja) 2019-06-04 2025-01-09 モレキュラー パートナーズ アクチェンゲゼルシャフト 組換えｆａｐ結合タンパク質及びそれらの使用
CA3138805A1 (en) 2019-06-04 2020-12-10 Johannes Schilling Designed ankyrin repeat domain with improved stability
CN114222757A (zh) 2019-06-04 2022-03-22 分子伴侣公司 重组4-1bb结合蛋白及其用途
WO2021116470A2 (en) 2019-12-11 2021-06-17 Molecular Partners Ag Recombinant peptide-mhc complex binding proteins and their generation and use
IL293698A (en) 2019-12-11 2022-08-01 Molecular Partners Ag Recombinant peptide-mhc complex binding proteins, their production and use
JP2023525518A (ja) 2020-05-06 2023-06-16 モレキュラー パートナーズ アクチェンゲゼルシャフト 新規アンキリンリピート結合タンパク質とその用途
US20240279290A1 (en) 2020-05-14 2024-08-22 Molecular Partners Ag Multispecific proteins
US20240279309A1 (en) 2020-05-14 2024-08-22 Molecular Partners Ag Recombinant cd40 binding proteins and their use
AU2021403658A1 (en) 2020-12-16 2023-06-29 Molecular Partners Ag Recombinant cd3 binding proteins and their use
AU2021403833A1 (en) 2020-12-16 2023-07-27 Molecular Partners Ag Novel slow-release prodrugs
EP4305063A1 (en) 2021-03-09 2024-01-17 Molecular Partners AG Protease cleavable prodrugs
CA3211368A1 (en) 2021-03-09 2022-09-15 Molecular Partners Ag Novel darpin based cd123 engagers
US20240317852A1 (en) 2021-03-09 2024-09-26 Molecular Partners Ag Novel darpin based cd33 engagers
BR112023018293A2 (pt) * 2021-03-09 2023-10-31 Molecular Partners Ag Acopladores de célula t multiespecíficos à base de darpin
WO2022215032A1 (en) 2021-04-09 2022-10-13 Molecular Partners Ag Novel darpin based cd70 engagers

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014501509A (ja) * 2010-11-26 2014-01-23 モレキュラー・パートナーズ・アーゲー 血清アルブミンに結合する設計リピートタンパク質
JP2018511327A (ja) * 2015-04-02 2018-04-26 モレキュラー パートナーズ アクチェンゲゼルシャフト 血清アルブミンに対する結合特異性を有する設計アンキリンリピートドメイン
JP2019512272A (ja) * 2016-03-21 2019-05-16 エルスター セラピューティクス， インコーポレイテッド 多重特異性および多機能性分子ならびにその使用
WO2019200022A1 (en) * 2018-04-11 2019-10-17 Inhibrx, Inc. Multispecific polypeptide constructs having constrained cd3 binding and related methods and uses
WO2020245746A1 (en) * 2019-06-04 2020-12-10 Molecular Partners Ag Multispecific proteins

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ANTIBODY THERAPEUTICS, vol. 2, no. 4, JPN6026003274, 5 November 2019 (2019-11-05), pages 79 - 87, ISSN: 0005784452 *
CURRENT HEMATOLOGIC MALIGNANCY REPORTS, vol. 16, no. 1, JPN6026003277, 25 February 2021 (2021-02-25), pages 89 - 96, ISSN: 0005784451 *

Also Published As

Publication number Publication date
CA3211381A1 (en) 2022-09-15
AU2022234894A9 (en) 2024-02-22
BR112023018293A2 (pt) 2023-10-31
AU2022234894A1 (en) 2023-10-05
US20230056271A1 (en) 2023-02-23
IL305677A (en) 2023-11-01
EP4304731A1 (en) 2024-01-17
MX2023010543A (es) 2023-10-13
WO2022190016A1 (en) 2022-09-15
KR20230155464A (ko) 2023-11-10
CO2023012681A2 (es) 2023-09-29
US20240254229A1 (en) 2024-08-01
US11834504B2 (en) 2023-12-05

Similar Documents

Publication Publication Date Title
JP2024509904A (ja) 新規なＤＡＲＰｉｎに基づく多重特異性Ｔ細胞エンゲージャ
EP3250611B1 (en) Car t-cells recognizing cancer-specific il 13r-alpha2
US20220298212A1 (en) Recombinant 4-1bb binding proteins and their use
US20240150475A1 (en) Novel darpin based cd123 engagers
US20250074994A1 (en) Novel darpin based cd70 engagers
US20240052033A1 (en) Recombinant cd3 binding proteins and their use
US20240317852A1 (en) Novel darpin based cd33 engagers
WO2024251628A1 (en) Recombinant cd16a binding proteins and their use
CN117157327A (zh) 基于darpin的新型多特异性t细胞接合物
CN113874396A (zh) 包含抗间皮素抗体、抗cd3抗体或抗egfr抗体的融合蛋白、包含所述融合蛋白的双特异性或三特异性抗体，及其用途
CN117242100A (zh) 基于DARPin的新型CD70接合物
WO2025146490A1 (en) Recombinant cd117 binding proteins and their use
CN117255803A (zh) 基于DARPin的新型CD33接合物
CN116802213A (zh) 重组cd3结合蛋白及其用途
CN121263440A (zh) 重组cd2结合蛋白及其用途
CN117177996A (zh) 基于DARPin的新型CD123接合物
HK40061276A (en) Fusion protein comprising anti-mesothelin antibody, anti-cd3 antibody or anti-egfr antibody, bispecific or trispecific antibody comprising same, and uses thereof
HK1245288B (en) Car t-cells recognizing cancer-specific il 13r-alpha2

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250310

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250310

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260129